Tretinoin Shortage: What Providers and Prescribers Need to Know in 2026

Tretinoin availability in 2026 presents two distinct clinical challenges: an active FDA-listed shortage of oral Tretinoin capsules affecting oncology centers and hematology practices, and fragmented topical Tretinoin availability at the pharmacy level affecting dermatology, primary care, and telehealth providers. This article provides a current clinical summary of both situations and practical guidance for managing patient care.

Oral Tretinoin (ATRA) Capsules: Active FDA Shortage

The FDA's current drug shortage database confirms oral Tretinoin (all-trans retinoic acid / ATRA) capsules remain in active shortage as of early 2026. This formulation is the standard of care in ATRA-ATO (tretinoin plus arsenic trioxide) regimens for acute promyelocytic leukemia (APL), and its unavailability poses direct patient safety risks.

For oncology providers managing APL, key management steps include:

Contact your institution's pharmacy director immediately when an APL patient is diagnosed to confirm supply availability before initiating treatment planning.

Engage your GPO (group purchasing organization) and specialty pharmaceutical distributors for alternative sourcing options.

Contact the FDA's Drug Shortage Staff (1-301-796-8240) for assistance identifying available supply and alternative manufacturers.

Monitor ASHP's drug shortage database (ashp.org/drug-shortages) for updated manufacturer availability and estimated resupply dates.

Document all shortage-related communication and clinical decisions in the patient record for regulatory and safety purposes.

Topical Tretinoin: Understanding the Access Gap

Topical Tretinoin is not on the FDA shortage list, but prescribers are increasingly fielding patient reports of difficulty filling prescriptions. The cause is multi-factorial:

Manufacturer discontinuations have reduced total market supply of specific topical formulations (Avita Cream discontinued by Mylan in 2025).

Formulation proliferation means pharmacies selectively stock only their most-demanded concentrations. Prescriptions for less-common strengths (0.08% gel, 0.1% cream) often require special ordering.

Demand surge from telehealth platforms has increased total prescriptions written, straining regional pharmacy inventory at peak refill periods.

Clinical Substitution Options for Topical Tretinoin

When patients cannot access their prescribed topical Tretinoin formulation, the following substitutions are clinically supported:

Concentration substitution within class:

Lower concentrations (0.025% or 0.04%) are generally well tolerated and appropriate for acne maintenance or photoaging in patients new to retinoids. Prescribing the lowest effective concentration reduces the frequency of stock-related issues.

Adapalene (Differin):

For acne, adapalene 0.1% (OTC) or 0.3% (Rx) is a clinically appropriate alternative. It demonstrates comparable efficacy to Tretinoin 0.025% with a more favorable tolerability profile. It can be used alongside benzoyl peroxide. Not FDA-approved for photoaging.

Tazarotene (Tazorac, Arazlo):

For acne and photoaging, tazarotene provides superior or comparable efficacy to Tretinoin in clinical trials. Arazlo 0.045% lotion has improved tolerability versus older tazarotene formulations. Cost is higher; check formulary coverage.

Compounding pharmacies:

Compounded Tretinoin at custom concentrations (e.g., 0.01%, 0.025%, 0.05%) in various bases can address specific patient needs or stocking gaps. Not insurance-covered; ensure compounding pharmacy has USP 795/797 compliance.

Prescribing Best Practices to Minimize Access Barriers

Dermatologists and primary care prescribers can implement several practical strategies to reduce patient access friction:

When clinically appropriate, write prescriptions that allow generic substitution and do not specify a formulation that is rarely stocked (e.g., avoid "Altreno only" unless medically necessary).

Consider a tiered prescription approach: write the target strength as the primary and note an acceptable alternative concentration if the primary is unavailable.

Coach patients to use pharmacy-finding tools (medfinder, GoodRx) and to call ahead before going to the pharmacy.

For patients on chronic Tretinoin therapy, consider 90-day prescriptions through mail-order pharmacies to reduce refill interruptions.

For insured patients, document the medical necessity of the specific formulation if prior authorization is required for non-generic versions.

Insurance and Prior Authorization Considerations

Generic Tretinoin cream and gel are generally covered by commercial insurance and Medicare Part D when prescribed for acne vulgaris (ICD-10 L70.x). Coverage for photoaging indications is inconsistent — many plans classify this as cosmetic and deny coverage. Providers should use the acne diagnosis code where clinically appropriate and document the medical rationale clearly.

Prior authorization is commonly required for brand-name Tretinoin products (Altreno, Retin-A Micro) and is often linked to step therapy requiring documentation that generic Tretinoin was trialed first. Ensure your office has current PA templates available and that staff are prepared to submit step therapy exception requests when clinically warranted.

How medfinder Supports Your Patients

When patients report difficulty filling their Tretinoin prescriptions, directing them to medfinder can save them significant time. medfinder contacts pharmacies near the patient's location, checks real-time stock of their specific medication, and texts results — removing the burden of calling multiple pharmacies. See our dedicated provider guide to helping patients find Tretinoin for additional clinical resources.